Penn Capital Management Company LLC Invests $251,000 in Aquestive Therapeutics, Inc. $AQST

Key Points

• Penn Capital Management Company LLC has acquired a new position in Aquestive Therapeutics, Inc. by purchasing 86,618 shares valued at approximately $251,000 in the first quarter.
• Aquestive Therapeutics reported q2 earnings with a loss of ($0.14), slightly better than the expected loss of ($0.18), and had quarterly revenue of $10 million.
• Analysts have given Aquestive Therapeutics a consensus rating of "Moderate Buy" with a target price of approximately $10.14, reflecting positive market sentiment.

Penn Capital Management Company LLC bought a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 86,618 shares of the company's stock, valued at approximately $251,000. Penn Capital Management Company LLC owned 0.09% of Aquestive Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its holdings in shares of Aquestive Therapeutics by 905.2% during the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after acquiring an additional 621,614 shares in the last quarter. Stifel Financial Corp boosted its holdings in shares of Aquestive Therapeutics by 315.4% during the 4th quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock valued at $1,419,000 after acquiring an additional 302,617 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Aquestive Therapeutics during the 1st quarter valued at $686,000. Harvey Capital Management Inc. boosted its holdings in shares of Aquestive Therapeutics by 86.8% during the 1st quarter. Harvey Capital Management Inc. now owns 499,570 shares of the company's stock valued at $1,449,000 after acquiring an additional 232,180 shares in the last quarter. Finally, Stonepine Capital Management LLC acquired a new position in Aquestive Therapeutics during the 4th quarter worth about $570,000. Institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Price Performance

Shares of NASDAQ AQST traded down $0.06 during midday trading on Friday, reaching $3.78. The company's stock had a trading volume of 382,970 shares, compared to its average volume of 1,511,315. Aquestive Therapeutics, Inc. has a 12-month low of $2.12 and a 12-month high of $5.80. The firm has a 50 day moving average price of $3.85 and a 200-day moving average price of $3.20. The stock has a market capitalization of $376.44 million, a P/E ratio of -5.41 and a beta of 1.99.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. The business had revenue of $10.00 million during the quarter, compared to analysts' expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, equities analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on AQST shares. Zacks Research raised Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 13th. Oppenheimer assumed coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $10.14.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.